HK1212886A1 - Low melting propionic acid derivative particles for use in oral dosage forms - Google Patents

Low melting propionic acid derivative particles for use in oral dosage forms

Info

Publication number
HK1212886A1
HK1212886A1 HK16100781.5A HK16100781A HK1212886A1 HK 1212886 A1 HK1212886 A1 HK 1212886A1 HK 16100781 A HK16100781 A HK 16100781A HK 1212886 A1 HK1212886 A1 HK 1212886A1
Authority
HK
Hong Kong
Prior art keywords
dosage forms
propionic acid
acid derivative
low melting
oral dosage
Prior art date
Application number
HK16100781.5A
Other languages
Chinese (zh)
Inventor
Saumitra Bagchi
Murali K Vuppala
Original Assignee
Mcneil-Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/789,797 external-priority patent/US20140256810A1/en
Application filed by Mcneil-Ppc Inc filed Critical Mcneil-Ppc Inc
Publication of HK1212886A1 publication Critical patent/HK1212886A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK16100781.5A 2012-09-18 2016-01-25 Low melting propionic acid derivative particles for use in oral dosage forms HK1212886A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702392P 2012-09-18 2012-09-18
US13/789,797 US20140256810A1 (en) 2013-03-08 2013-03-08 Low melting propionic acid derivative particles for use in oral dosage forms
PCT/US2013/059918 WO2014047001A1 (en) 2012-09-18 2013-09-16 Low melting propionic acid derivative particles for use in oral dosage forms

Publications (1)

Publication Number Publication Date
HK1212886A1 true HK1212886A1 (en) 2016-06-24

Family

ID=49231643

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15110267.8A HK1209372A1 (en) 2012-09-18 2015-10-19 Low melting propionic acid derivative particles for use in oral dosage forms
HK16100781.5A HK1212886A1 (en) 2012-09-18 2016-01-25 Low melting propionic acid derivative particles for use in oral dosage forms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15110267.8A HK1209372A1 (en) 2012-09-18 2015-10-19 Low melting propionic acid derivative particles for use in oral dosage forms

Country Status (8)

Country Link
EP (1) EP2897584A1 (en)
CN (1) CN104640537A (en)
AU (1) AU2013318356A1 (en)
BR (1) BR112015005876A2 (en)
CA (1) CA2884119A1 (en)
HK (2) HK1209372A1 (en)
RU (1) RU2015114540A (en)
WO (1) WO2014047001A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015110511A (en) * 2014-03-28 2016-10-20 МакНЕЙЛ-ППС, ИНК. PARTICULAR DERIVATIVE ACID PARTICLES FOR DIRECT PRESS
CN109956860B (en) * 2019-03-08 2022-03-01 天津大学 Preparation method of ibuprofen spherical crystal
CN112826798B (en) * 2019-11-25 2023-04-07 上海博志研新药物技术有限公司 Ibuprofen pharmaceutical composition, preparation method and application

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
DE3440288A1 (en) 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien PHARMACEUTICAL PREPARATION WITH A CONTENT OF AT LEAST ONE Mucous-irritating SUBSTANCE OR THE LIKE, PARTICULARLY PROFESSIONALS, AND METHOD FOR THE PRODUCTION THEREOF
US4923898A (en) 1984-12-26 1990-05-08 Analgesic Associates Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
CA2063141C (en) 1989-08-04 1997-03-04 Edward J. Roche Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
IT1246383B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR MASKING THE TASTE OF DRUGS
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
WO1994005260A1 (en) 1992-09-03 1994-03-17 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
IT1264855B1 (en) 1993-06-21 1996-10-17 Zambon Spa PHARMACEUTICAL COMPOSITIONS CONTAINING S (+) - 2- (4-ISOBUTYLPHENYL) PROPIONIC ACID SALTS WITH BASIC AMINO ACIDS
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
TW442287B (en) 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
NZ333474A (en) 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
FR2811912B1 (en) 2000-07-21 2003-02-07 Gattefosse Ets Sa PROCESS FOR COATING SOLID PARTICLES WITH A HEAT-MELTING AGENT, AND SOLID PARTICLES THUS COATED
GB0113841D0 (en) 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
JP2007516259A (en) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー Method for preparing mixed phase co-crystal with activator
JP4629730B2 (en) * 2004-12-10 2011-02-09 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ Pharmaceutical composition for improving ease of drug and method for preparing the same
AU2007308986A1 (en) 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition

Also Published As

Publication number Publication date
HK1209372A1 (en) 2016-04-01
WO2014047001A1 (en) 2014-03-27
BR112015005876A2 (en) 2017-07-04
RU2015114540A (en) 2016-11-10
AU2013318356A1 (en) 2015-03-19
EP2897584A1 (en) 2015-07-29
CA2884119A1 (en) 2014-03-27
CN104640537A (en) 2015-05-20

Similar Documents

Publication Publication Date Title
HK1209343A1 (en) Etanercept formulations exhibiting marked reduction in sub-visible particles
IL227383A0 (en) Oral dosage forms for modified release comprising tasocitinib
EP2739288A4 (en) Progesterone containing oral dosage forms and related methods
HRP20160989T1 (en) Solution for oral administration
HK1199821A1 (en) Oral pharmaceutical composition
SG11201404728VA (en) Nanoparticle paste formulations and methods for production and use thereof
HK1199822A1 (en) Oral pharmaceutical composition
HK1187335A1 (en) Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals 3--
PT2726064T (en) Controlled release oral dosage form comprising oxycodone
PL2747776T3 (en) Compounds for use in boosting coagulation
HK1215545A1 (en) Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
EP2668852A4 (en) Composition for oral administration
HK1198466A1 (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
HK1212886A1 (en) Low melting propionic acid derivative particles for use in oral dosage forms
HK1212889A1 (en) Sustained release oral dosage forms comprising low melting propionic acid derivative particles
ZA201502613B (en) Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles
IL239975A0 (en) Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy